Equities research analysts predict that DelMar Pharmaceuticals Inc (NASDAQ:DMPI) will post ($0.20) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals posted earnings per share of ($0.80) in the same quarter last year, which would suggest a positive year-over-year growth rate of 75%. The company is expected to report its next earnings report on Monday, February 10th.
According to Zacks, analysts expect that DelMar Pharmaceuticals will report full year earnings of ($1.20) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($0.90) per share. Zacks’ earnings per share calculations are an average based on a survey of analysts that that provide coverage for DelMar Pharmaceuticals.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.59).
Shares of DelMar Pharmaceuticals stock traded down $0.01 during trading on Friday, reaching $0.77. 471,300 shares of the company’s stock were exchanged, compared to its average volume of 713,306. The company has a market cap of $2.08 million, a P/E ratio of -0.24 and a beta of 1.30. The firm’s 50-day moving average price is $0.56 and its 200 day moving average price is $1.19. DelMar Pharmaceuticals has a 1-year low of $0.40 and a 1-year high of $6.80.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Recommended Story: What Factors Can Affect Return on Equity?
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
